Atopic Dermatitis / Eczema Clinical Trials

Regeneron protocol R668-AD-1652: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to 11 Years of Age, With Severe Atopic Dermatitis -ACTIVE/NOT ENROLLING

  •  A Phase III clinical trial investigating a biologic IL-4 inhibitor (dupilumab) in subjects ages ≥6 to 11 years old with severe atopic dermatitis.

Regeneron protocol R668-AD-1434: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to 18 Years of Age With Atopic Dermatitis -ACTIVE/ENROLLING BY INVITATION ONLY

  • A Phase III extension trial for patients ages 6 months to 18 years of age who have previously participated in a clinical trial for dupilumab.

Dermira protocol DRM06-AD01: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial To Evaluate The Efficacy And Safety Of Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis-ACTIVE/NOT ENROLLING

  • A Phase II clinical trial investigating a biologic IL-13 inhibitor for patients 18 years of age or older with moderate to severe atopic dermatitis.

Regeneron protocol R668-AD-1762: A Prospective Observational Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis-CURRENTLY ENROLLING

  • A 5 year observational registry for adult patients who have been newly-prescribed Dupixent (dupilumab) for moderate to severe atopic dermatitis.

Lilly protocol I4V-MC-JAIW: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis   -CURRENTLY ENROLLING

  • A phase III trial investigating an oral JAK inhibitor for patients 18 years and older with moderate to severe atopic dermatitis.
Franklin BioScience protocol 001: An Observational Study on the Treatment of Eczematous Conditions with a Topical Cannabinoid Gel Designed to Improve the Appearance
of Affected Skin -CURRENTLY ENROLLING
  • A study investigating the use of a topical cannabinoid gel in adults 21 years of age and older with mild to moderate atopic dermatitis.
  • A phase III trial investigating an oral neurokinin-1 agonist in adults age 18-70 with mild, moderate, or severe atopic dermatitis.
  • A Phase II trial investigating a new biologic therapy against and in combination with dupixent.
  • A Phase III study investigating a new JAK inhibitor head to head against dupixent.
  • A Phase III trial investigating a JAK inhibitor for use in adolescents.
  • A Phase II study investigating a new biologic therapy for adults with atopic dermatitis.
  • A phase II study investigating the use of Skyrizi in adults with atopic dermatitis.